H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review

GlobalData, April 2013, Pages: 46

Summary

H. Lundbeck A/S (Lundbeck) is a pharmaceutical company, involved in the research, development, manufacturing and marketing of pharmaceuticals for the treatment of diseases related to the central nervous system (CNS), including depression, schizophrenia, Parkinson’s disease, Alzheimer’s disease, Huntington's disease, epilepsy and insomnia. Operating through its global subsidiaries, the company has production units in Denmark, Italy, France, and Mexico, and research facilities in Denmark and the US. The product portfolio of the company consists of Cipralex/Lexapro, Ebixa, Azilect, Xenazine, Sabril, Sycrest and Onfi.

H. Lundbeck AS Key Recent Developments

Feb 20, 2013: Lundbeck To Elect New Chairman
Jan 02, 2013: Vernalis And H.Lundbeck A/S Achieve Third Research Milestone
Dec 19, 2012: Lundbeck Provides Update On Investments In Product Development And Product Launches
Dec 13, 2012: Genmab Reaches Third Milestone In Lundbeck Collaboration
Nov 09, 2012: Lundbeck To Set Up First Asian Factory In Tianjin, China

This comprehensive SWOT profile of H. Lundbeck AS provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

List of Tables
List of Figures
Section 1 - About the Company
H. Lundbeck A/S - Key Facts
H. Lundbeck A/S - Key Employees
H. Lundbeck A/S - Key Employee Biographies
H. Lundbeck A/S - Major Products and Services
H. Lundbeck A/S - Pharmaceutical Pipeline Products Data
H. Lundbeck A/S, Pipeline Products by Therapy Area
H. Lundbeck A/S, Pipeline Products by Development Phase
H. Lundbeck A/S - History
H. Lundbeck A/S - Company Statement
H. Lundbeck A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
H. Lundbeck A/S - Business Description
H. Lundbeck A/S - Corporate Strategy
H. Lundbeck A/S - SWOT Analysis
SWOT Analysis - Overview
H. Lundbeck A/S - Strengths
Strength - Widespread Geographic Presence
Strength - Sturdy Research and Development Activities
Strength - Broad Portfolio of CNS Therapeutics
H. Lundbeck A/S - Weaknesses
Weakness - Product Discontinuation
H. Lundbeck A/S - Opportunities
Opportunity - Market Potential-Central Nervous System
Opportunity - Strategic Alliances
Opportunity - Pipeline Products
H. Lundbeck A/S - Threats
Threat - Intense Competition
Threat - Uncertain R&D Outcomes
H. Lundbeck A/S - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
H. Lundbeck A/S, Recent Deals Summary
Section 5 – Company’s Recent Developments
H. Lundbeck A/S, Recent Developments
Feb 20, 2013: Lundbeck To Elect New Chairman
Jan 02, 2013: Vernalis And H.Lundbeck A/S Achieve Third Research Milestone
Dec 19, 2012: Lundbeck Provides Update On Investments In Product Development And Product Launches
Dec 13, 2012: Genmab Reaches Third Milestone In Lundbeck Collaboration
Nov 09, 2012: Lundbeck To Set Up First Asian Factory In Tianjin, China
Nov 07, 2012: Lundbeck Reports Revenue Of DKK3.6 Billion In Q3 2012
Aug 08, 2012: Lundbeck Reports Revenue Of DKK3.6 Billion In Q2 2012
Jul 25, 2012: Lundbeck Disagrees With Statement Of Objections Issued By European Commission
Jun 14, 2012: Lundbeck Plans To Establish More Flexible Commercial Organization In Europe, Eliminate 600 Jobs
Jun 14, 2012: Lundbeck Plans To Establish More Flexible Commercial Organization In Europe, Eliminate 600 Jobs
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
H. Lundbeck A/S, Key Facts
H. Lundbeck A/S, Key Employees
H. Lundbeck A/S, Key Employee Biographies
H. Lundbeck A/S, Major Products and Services
H. Lundbeck A/S, Number of Pipeline Products by Therapy Area
H. Lundbeck A/S, Number of Pipeline Products by Development Stage
H. Lundbeck A/S, Pipeline Products By Therapy Area and Development Phase
H. Lundbeck A/S, History
H. Lundbeck A/S, Subsidiaries
H. Lundbeck A/S, Key Competitors
H. Lundbeck A/S, Ratios based on current share price
H. Lundbeck A/S, Annual Ratios
H. Lundbeck A/S, Interim Ratios
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
H. Lundbeck A/S, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
H. Lundbeck A/S, Pipeline Products by Therapy Area
H. Lundbeck A/S, Pipeline Products by Development Phase
H. Lundbeck A/S, Performance Chart (2008 - 2012)
H. Lundbeck A/S, Ratio Charts
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
H. Lundbeck A/S, Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Aerospace and Defense Industry - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Defense Robotics - Global Strategic Business Report
• International Military and Government Helicopter Survey
• The Global UAV Payload Market 2012-2022